NCT06491342

Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease

PROBIOTIC SUPPLEMENT VERSUS PLACEBO FOR DECREASE STEATOSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Phramongkutklao College of Medicine and Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

Detailed description

Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial by access liver biochemistry, MRI-PDFF, fibroscan and metabolic profile

Conditions

• Fatty Liver, Nonalcoholic

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Probiotic	Probiotic-Lactobacillus Zeae and Lactobacillus reuteri
DIETARY_SUPPLEMENT	Placebo	placebo

Timeline

• Start date: 2024-07-25
• Primary completion: 2025-04-22
• Completion: 2025-05-28
• First posted: 2024-07-09
• Last updated: 2025-07-25

Locations

2 sites across 1 country: Thailand